Hong Kong: Venus Medtech raises HK$2.6bn

Enthusiastic demand and a desire for something other than biotech paper have seen Venus Medtech raise HK$2.6bn (US$331m) in its IPO in Hong Kong. The company has sold 78.5 million shares at the top of the HK$29 to HK$33 a share indicative range. The deal attracted five cornerstone investors – hedge funds and sovereign wealth…

You must be a HMI Subscriber to view this content.

Subscribe Now »